Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quizartinib QT assessment in healthy subjects under rapid heart rate acceleration
NCT06772246Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Oct 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, single-blind, single-arm trial of quizartinib in acute myeloid leukemia (AML), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Change in Heart Rate at Day 2. Started Oct 2024; status: completed.
02
Drugs
quizartinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06772246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06772246.